icon-facebookicon-instagramicon-pinteresticon-soundcloudicon-twittericon-youtube
AMaRC 18-01 - RECRUITMENT CLOSED

STUDY TITLE

An exploratory study of Venetoclax in combination with Bortezomib-Cyclophosphamide-Dexamethasone (VCD) induction therapy in newly diagnosed transplant eligible (NDTE MM) multiple myeloma with proteomic correlative studies

 

STUDY DESIGN

Multicentre, single arm, open label trial

 

CORRELATIVE STUDIES

Blood and bone marrow samples will be collected as part of the trial, and studied for molecular biomarkers and disease response

 

TRIAL PRINCIPAL INVESTIGATOR

Professor Andrew Spencer

 

TIME FRAME

2018 – 2021

 

PARTICIPANTS

45 newly diagnosed patients with multiple myeloma, who will receive an Autologous Stem Cell Transplant (ASCT)

 

CURRENT ENROLMENT 

17

 

STATUS

Closed to Recruitment

 

SITE LOCATIONS